Uvax Bio Appoints Kevin O’Neill as Interim Chief Executive Officer
04 Feb 2025 //
GLOBENEWSWIRE
Uvax Bio Announces Interim Results from HIV-1 Vaccine Ph 1
19 Nov 2024 //
BUSINESSWIRE
Uvax Announces Dosing of First Participant in Phase 1 Evaluating Two Vaccines
30 Jan 2024 //
BUSINESSWIRE